Renato Fuchs, PhD
Renato Fuchs, PhD
Process Development and Manufacturing
For the past 33 Years Dr. Fuchs has held major Operations Management positions in the Biotechnology and Pharmaceutical Industry. Dr. Fuchs has developed the Process Development and Manufacturing Organizations in a number of companies. In doing so, he has managed technology development, technology transfer and implementation and finally the manufacturing and CMC regulatory approvals of pharmaceutical products worldwide. Dr. Fuchs has also directed the design, construction and start-up of manufacturing facilities. He has been a member of Industrial Advisory Boards at Lehigh University, Berkley and MIT and is currently a member of the Board of Directors of Auxilium Pharmaceuticals. Dr. Fuchs is a member of the National Academy of Engineering.
Specifically, Dr. Fuchs has served as Senior Vice President, Manufacturing and Technical Operations at Altus Pharmaceuticals from August of 2006 to June 2007, at which point he retired and became a private consultant. The previous 5 years Dr. Fuchs served as Senior Vice President, Manufacturing and Operations at Shire HGT (previously Transkaryotic Therapies, Inc.), where he was responsible for manufacturing, materials management, process development and engineering operations. At Shire he was instrumental in organizing the development of the processes and manufacturing of genetic metabolic defficiency proteins. Previous to his tenure at Shire HGT, Dr. Fuchs spent nine years at Chiron Corporation as Sr. Vice president of Technical Operations ( most recently as Senior Vice President of BioPharmaceuticals), with responsibility for overseeing and coordinating Chiron’s Technical Operations as well as manage critical domestic and international projects. The assignment at Chiron involved bacterial, yeast and mammalian cell processes for therapeutics (Interferon Beta, Interleukin 2) and a multiplicity of vaccines. From 1988 to 1993, Dr. Fuchs held advancing Vice President-level positions at Centocor, Inc. where he was instrumental in developing the antibody manufacturing technology including Remicade and Reopro. Previous to this he spent 15 years at Schering-Plough Corporation developing antibiotic manufacturing processes and pioneering the development and manufacturing of recombinant proteins such as Interferon Alpha.
Dr. Fuchs received a B.S. in Chemical Engineering from the Universidad Del Valle, Cali, Colombia, and a M.S. and Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.